1. A compound of formula I
wherein
R1 is halogen, \u2014OR1\u2032, \u2014SR1\u2033, morpholin, heterocycloalkyl, aryl or 5-or 6-membered heteroaryl;
R1\u2032 and R1\u2033 are each independently hydrogen, lower alkyl, lower alkyl substituted by halogen, \u2014(CH2)x-cycloalkyl or \u2014(CH2)x-aryl;
R2 is \u2014S(O)2-lower alkyl, \u2014S(O)2NH-lower alkyl, or CN;
is an aromatic or partially aromatic bicyclic amine, having one or two additional N-atoms selected from the group consisting of
and wherein one additional N-ring atom of the aromatic or partially aromatic bicyclic amine can be available in form of its oxide
R3 to R10 are each independently hydrogen, hydroxy, halogen, \u2550O, lower alkyl, cycloalkyl, heterocycloalkyl, lower alkoxy, CN, NO2, NH2, aryl, 5- or 6-membered heteroaryl containing one, two or three heteroatoms selected from the group consisting of oxygen, sulphur and nitrogen, \u2014NH-lower alkyl, \u2014N(lower alkyl)2, cyclic amide, \u2014C(O)-cyclic amide, S-lower alkyl, \u2014S(O)2-lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, lower alkyl substituted by hydroxy, \u2014O\u2014(CH2)y-lower alkoxy, \u2014O(CH2)yC(O)N(lower alkyl)2, \u2014C(O)-lower alkyl, \u2014O\u2014(CH2)x-aryl, \u2014O\u2014(CH2)x-cycloalkyl, \u2014O\u2014(CH2)x-heterocycloalkyl, \u2014C(O)O-lower alkyl, \u2014C(O)\u2014NH-lower alkyl, \u2014C(O)\u2014N(lower alkyl)2, 2-oxy-5-aza-bicyclo2.2.1hept-5-yl or 3-oxa-8-aza-bicyclo3.2.1oct-8-yl;
R and R\u2032, are each independently hydrogen or lower alkyl;
wherein heteroaryl is selected from the group consisting of furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, isothiazolyl, isoxazolyl, pyridinyl, pyrazinyl, and pyrimidinyl; and
heterocycloalkyl is selected from the group consisting of tetrahydropyran-2, 3 or 4-yl, tetrahydrofuran-2 or 3-yl, oxetan-3-yl, and 1,4dioxin-2-yl;
and wherein all aryl-, morpholin, heterocycloalkyl- or 5 or 6 membered heteroaryl groups as defined for R1, R1\u2032, R1\u2033 and R3 to R10 are unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, \u2550O, halogen, lower alkyl, phenyl, lower alkyl substituted by halogen and lower alkoxy;
n, m, o, p, q, r, s and t are each independently 1 or 2;
x is 0, 1 or 2; and
y is 1 or 2;
or a pharmaceutically acceptable acid addition salt thereof.
2. A compound of claim 1, having formula IB
wherein
R1 is halogen, \u2014OR1\u2032, \u2014SR1\u2033, morpholin, heterocycloalkyl, aryl or 5- or 6-membered heteroaryl;
R1\u2032 and R1\u2033 are each independently hydrogen, lower alkyl, lower alkyl substituted by halogen, \u2014(CH2)x-cycloalkyl or \u2014(CH2)x-aryl;
R2 is \u2014S(O)2-lower alkyl, \u2014S(O)2NH-lower alkyl, or CN;
and wherein the additional N-ring atom of the bicyclic amine can be available in form of its oxide
R4 is hydrogen, hydroxy, halogen, \u2550O, lower alkyl, cycloalkyl, heterocycloalkyl, lower alkoxy, CN, NO2, NH2, aryl, 5- or 6-membered heteroaryl containing one, two or three heteroatoms selected from the group consisting of oxygen, sulphur and nitrogen, \u2014NH-lower alkyl, \u2014N(lower alkyl)2, cyclic amide, \u2014C(O)-cyclic amide, S-lower alkyl, \u2014S(O)2-lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, lower alkyl substituted by hydroxy, \u2014O\u2014(CH2)y-lower alkoxy, \u2014O(CH2)yC(O)N(lower alkyl)2, \u2014C(O)-lower alkyl, \u2014O\u2014(CH2)x-aryl, \u2014O\u2014(CH2)x-cycloalkyl, \u2014O\u2014(CH2)x-heterocycloalkyl, \u2014C(O)O-lower alkyl, \u2014C(O)\u2014NH-lower alkyl, \u2014C(O)\u2014N(lower alkyl)2, 2-oxy-5-aza-bicyclo2.2.1hept-5-yl or 3-oxa-8-aza-bicyclo3.2.1oct-8-yl;
R and R\u2032 are each independently hydrogen or lower alkyl;
wherein heteroaryl is selected from the group consisting of furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, isothiazolyl, isoxazolyl, pyridinyl, pyrazinyl, and pyrimidinyl; and
heterocycloalkyl is selected from the group consisting of tetrahydropyran-2, 3 or 4-yl, tetrahydrofuran-2 or 3-yl, oxetan-3-yl, and 1,4dioxin-2-yl;
and wherein all aryl-, morpholin, heterocycloalkyl- or 5 or 6 membered heteroaryl groups as defined for R1, R1\u2032, R1\u2033 and R4 are unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, \u2550O, halogen, lower alkyl, phenyl, lower alkyl substituted by halogen and lower alkoxy;
m is 1 or 2;
x is 0, 1 or 2; and
y is 1 or 2;
or a pharmaceutically acceptable acid addition salt thereof.
3. A compound of claim 2, selected from the group consisting of
(2-cyclobutylmethoxy-5-methanesulfonyl-phenyl)-(3-trifluoromethyl-5,7-dihydro -pyrrolo3,4-bpyridin-6-yl)-methanone,
(2-isobutoxy-5-methanesulfonyl-phenyl)-(3-trifluoromethyl-5,7-dihydro-pyrrolo3,4-bpyridin-6-yl)-methanone,
5-methanesulfonyl-2-((R)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl-(3-trifluoromethyl-5,7-dihydro-pyrrolo3,4-bpyridin-6-yl)-methanone,
(4\u2032-fluoro-4-methanesulfonyl-biphenyl-2-yl)-(3-trifluoromethyl-5,7-dihydro-pyrrolo3,4-bpyridin-6-yl)-methanone,
(3\u2032,4\u2032-difluoro-4-methanesulfonyl-biphenyl-2-yl)-(3-trifluoromethyl-5,7-dihydro-pyrrolo3,4-bpyridin-6-yl)-methanone,
5-methanesulfonyl-2-(2,2,3,3,3-pentafluoro-propoxy)-phenyl-(3-trifluoromethyl-5,7-dihydro-pyrrolo 3,4-bpyridin-6-yl)-methanone,
5-methanesulfonyl-2-(2,2,3,3-tetrafluoro-propoxy)-phenyl-(3-trifluoromethyl-5,7-dihydro-pyrrolo 3,4-bpyridin-6-yl)-methanone,
5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl-(2-methyl-3-trifluoromethyl-5,7-dihydro-pyrrolo3,4-bpyridin-6-yl)-methanone,
3-(4-fluoro-phenyl)-5,7-dihydro-pyrrolo3,4-bpyridin-6-yl-5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl-methanone,
5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl-(3-trifluoromethyl-5,7-dihydro-pyrrolo3,4-bpyridin-6-yl)-methanone and
2-(4-fluoro-phenyl)-5,7-dihydro-pyrrolo3,4-bpyridin-6-yl-5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl-methanone.
4. A compound of claim 1, having formula IC
wherein
R1 is halogen, \u2014OR1\u2032, \u2014SR1\u2033, morpholin, heterocycloalkyl, aryl or 5- or 6-membered heteroaryl;
R1\u2032 and R1\u2033 are each independently hydrogen, lower alkyl, lower alkyl substituted by halogen, \u2014(CH2)x-cycloalkyl or \u2014(CH2)x-aryl;
R2 is \u2014S(O)2-lower alkyl, \u2014S(O)2NH-lower alkyl, or CN;
and wherein the additional N-ring atom of the bicyclic amine can be available in form of its oxide
R5 is hydrogen, hydroxy, halogen, \u2550O, lower alkyl, cycloalkyl, heterocycloalkyl, lower alkoxy, CN, NO2, NH2, aryl, 5- or 6-membered heteroaryl containing one, two or three heteroatoms selected from the group consisting of oxygen, sulphur and nitrogen, \u2014NH-lower alkyl, \u2014N(lower alkyl)2, cyclic amide, \u2014C(O)-cyclic amide, S-lower alkyl, \u2014S(O)2-lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, lower alkyl substituted by hydroxy, \u2014O\u2014(CH2)y-lower alkoxy, \u2014O(CH2)yC(O)N(lower alkyl)2, \u2014C(O)-lower alkyl, \u2014O\u2014(CH2)x-aryl, \u2014O\u2014(CH2)x-cycloalkyl, \u2014O\u2014(CH2)x-heterocycloalkyl, \u2014C(O)O-lower alkyl, \u2014C(O)\u2014NH-lower alkyl, \u2014C(O)\u2014N(lower alkyl)2, 2-oxy-5-aza-bicyclo2.2.1hept-5-yl or 3-oxa-8-aza-bicyclo3.2.1oct-8-yl;
R and R\u2032 are each independently hydrogen or lower alkyl;
wherein heteroaryl is selected from the group consisting of furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, isothiazolyl, isoxazolyl, pyridinyl, pyrazinyl, and pyrimidinyl; and
heterocycloalkyl is selected from the group consisting of tetrahydropyran-2, 3 or 4-yl, tetrahydrofuran-2 or 3-yl, oxetan-3-yl, and 1,4dioxin-2-yl;
and wherein all aryl-, cycloalkyl-, cyclic amide, heterocycloalkyl- or 5 or 6 membered heteroaryl groups as defined for R1, R1\u2032, R1\u2033 and R5 are unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, \u2550O, halogen, lower alkyl, phenyl, lower alkyl substituted by halogen and lower alkoxy;
o is 1 or 2;
x is 0, 1 or 2; and
y is 1 or 2;
or a pharmaceutically acceptable acid addition salt thereof.
5. A compound of claim 4, selected from the group consisting of
(2-cyclobutylmethoxy-5-methanesulfonyl-phenyl)-(6-trifluoromethyl-1,3-dihydro-pyrrolo3,4-cpyridin-2-yl)-methanone,
(4\u2032-fluoro-4-methanesulfonyl-biphenyl-2-yl)-(6-trifluoromethyl-1,3-dihydro-pyrrolo3,4-cpyridin-2-yl)-methanone,
(3\u2032,4\u2032-difluoro-4-methanesulfonyl-biphenyl-2-yl)-(6-trifluoromethyl-1,3-dihydro-pyrrolo3,4-cpyridin-2-yl)-methanone,
5-methanesulfonyl-2-(2,2,3,3,3-pentafluoro-propoxy)-phenyl-(6-trifluoromethyl-1,3-dihydro-pyrrolo3,4-cpyridin-2-yl)-methanone,
5-methanesulfonyl-2-(2,2,3,3-tetrafluoro-propoxy)-phenyl-(6-trifluoromethyl-1,3-dihydro-pyrrolo 3,4-cpyridin-2-yl)-methanone,
6-(4-fluoro-phenyl)-1,3-dihydro-pyrrolo3,4-cpyridin-2-yl-5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl-methanone and
5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl-(6-morpholin-4-yl-1,3-dihydro-pyrrolo3,4-cpyridin-2-yl)-methanone.
6. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I
wherein
R1 is halogen, \u2014OR1\u2032, \u2014SR1\u2033, morpholin, heterocycloalkyl, aryl or 5- or 6-membered heteroaryl;
R1\u2032 and R1\u2033 are each independently hydrogen, lower alkyl, lower alkyl substituted by halogen, \u2014(CH2)x-cycloalkyl or \u2014(CH2)x-aryl;
R2 is \u2014S(O)2-lower alkyl, \u2014S(O)2NH-lower alkyl, or CN;
is an aromatic or partially aromatic bicyclic amine, having one or two additional N-atom selected from the group consisting of
and wherein one additional N-ring atom of the aromatic or partially aromatic bicyclic amine can be available in form of its oxide
R3 to R10 are each independently hydrogen, hydroxy, halogen, \u2550O, lower alkyl, cycloalkyl, heterocycloalkyl, lower alkoxy, CN, NO2, NH2, aryl, 5- or 6-membered heteroaryl containing one, two or three heteroatoms selected from the group consisting of oxygen, sulphur and nitrogen, \u2014NH-lower alkyl, \u2014N(lower alkyl)2, cyclic amide, \u2014C(O)-cyclic amide, S-lower alkyl, \u2014S(O)2-lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, lower alkyl substituted by hydroxy, \u2014O\u2014(CH2)y-lower alkoxy, \u2014O(CH2)yC(O)N(lower alkyl)2, \u2014C(O)-lower alkyl, \u2014O\u2014(CH2)x-aryl, \u2014O\u2014(CH2)x-cycloalkyl, \u2014O\u2014(CH2)x-heterocycloalkyl, \u2014C(O)O-lower alkyl, \u2014C(O)\u2014NH-lower alkyl, \u2014C(O)\u2014N(lower alkyl)2, 2-oxy-5-aza-bicyclo2.2.1hept-5-yl or 3-oxa-8-aza-bicyclo3.2.1oct-8-yl;
R, R\u2032, are each independently hydrogen or lower alkyl;
wherein heteroaryl is selected from the group consisting of furanyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, thiazolyl, isothiazolyl, isoxazolyl, pyridinyl, pyrazinyl, and pyrimidinyl; and
heterocycloalkyl is selected from the group consisting of tetrahydropyran-2, 3 or 4-yl, tetrahydrofuran-2 or 3-yl, oxetan-3-yl, and 1,4dioxin-2-yl;
and wherein all aryl-, morpholin, heterocycloalkyl- or 5 or 6 membered heteroaryl groups as defined for R1, R1\u2032, R1\u2033 and R3 to R10 are unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, \u2550O, halogen, lower alkyl, phenyl, lower alkyl substituted by halogen and lower alkoxy;
n, m, o, p, q, r, s and t are each independently 1 or 2;
x is 0, 1 or 2; and
y is 1 or 2;
or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A magnetic resonance imaging (MRI) system comprising:
at least one pole piece including a plurality of members; and
at least two grain-oriented sheets included within each of the members, wherein a direction of easy magnetization of a first of the at least two grain-oriented sheets is different than a direction of easy magnetization of a second of the at least two grain-oriented sheets.
2. An MRI system in accordance with claim 1 further comprising a third grain-oriented sheet stacked together with the first and the second grain-oriented sheets, wherein the direction of easy magnetization of the second grain-oriented sheet forms an angle of approximately sixty degrees relative to the direction of easy magnetization of the first grain-oriented sheet, and a direction of easy magnetization of the third grain-oriented sheet forms an angle of approximately sixty degrees relative to the direction of easy magnetization of the second grain-oriented sheet.
3. An MRI system in accordance with claim 2 wherein the second grain-oriented sheet is between the first and third grain-oriented sheets.
4. An MRI system in accordance with claim 1 further comprising a third grain-oriented sheet stacked together with the first and the second grain-oriented sheets, wherein the direction of easy magnetization of the second grain-oriented sheet forms an angle of approximately forty-five degrees relative to the direction of easy magnetization of the first grain-oriented sheet, and a direction of easy magnetization of the third grain-oriented sheet forms an angle of approximately forty-five degrees relative to the direction of easy magnetization of the second grain-oriented sheet.
5. An MRI system in accordance with claim 1 further comprising at least a pair of oppositely-facing magnets, each of the magnets having a center, the at least two sheets are stacked in a direction substantially parallel to a line extending substantially perpendicularly to the magnet centers.
6. An MRI system in accordance with claim 1 further comprising at least a pair of oppositely-facing magnets, each of the magnets having a center, the at least two sheets are stacked in a direction substantially perpendicular to a line extending substantially perpendicularly to the magnet centers.
7. An MRI system in accordance with claim 1 wherein each of the at least two sheets is fabricated from grain-oriented materials, wherein the grain-oriented materials include at least one of iron and aluminum, a combination of iron, aluminum and silicon, a combination of nickel and iron, and a combination of iron and silicon.
8. An MRI system in accordance with claim 1 wherein the second grain-oriented sheet has a coercive force that is greater than a coercive force of the first grain-oriented sheet.
9. An imaging system comprising at least one pole piece comprising at least two grain-oriented sheets that are stacked together, wherein a direction of easy magnetization of a first of the at least two grain-oriented sheets is different than a direction of easy magnetization of a second of the at least two grain-oriented sheets.
10. An imaging system in accordance with claim 1 further comprising a third grain-oriented sheet stacked together with the first and the second grain-oriented sheets, wherein the direction of easy magnetization of the second grain-oriented sheet forms an angle of approximately sixty degrees relative to the direction of easy magnetization of the first grain-oriented sheet, and a direction of easy magnetization of the third grain-oriented sheet forms an angle of approximately sixty degrees relative to the direction of easy magnetization of the second grain-oriented sheet.
11. An imaging system in accordance with claim 10 wherein the second grain-oriented sheet is between the first and third grain-oriented sheets.
12. An imaging system in accordance with claim 1 further comprising a third grain-oriented sheet stacked together with the first and the second grain-oriented sheets, wherein the direction of easy magnetization of the second grain-oriented sheet forms an angle of approximately forty-five degrees relative to the direction of easy magnetization of the first grain-oriented sheet, and a direction of easy magnetization of the third grain-oriented sheet forms an angle of approximately forty-five degrees relative to the direction of easy magnetization of the second grain-oriented sheet.
13. An imaging system in accordance with claim 9 further comprising at least a pair of oppositely-facing magnets, each of the magnets having a center, the at least two sheets are stacked in a direction substantially parallel to a line extending substantially perpendicularly to the magnet centers.
14. An imaging system in accordance with claim 9 further comprising at least a pair of oppositely-facing magnets, each of the magnets having a center, the at least two sheets are stacked in a direction substantially perpendicular to a line extending substantially perpendicularly to the magnet centers.
15. An imaging system in accordance with claim 9 wherein each of the at least two sheets is fabricated from grain-oriented materials, wherein the grain-oriented materials include at least one of iron and aluminum, a combination of iron, aluminum and silicon, a combination of nickel and iron, and a combination of iron and silicon.
16. An imaging system in accordance with claim 9 wherein the second grain-oriented sheet has a coercive force that is greater than a coercive force of the first grain-oriented sheet.